KALA BIO, Inc. stockholders voted to approve an amendment to the Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Common Stock at a ratio between 1-for-2 and 1-for-300. The specific ratio will be determined by the Board in its sole discretion and announced publicly when implemented. Additionally, shareholders elected Yonatan Colman and Brendan Purdy as Class III directors, approved an advisory vote on executive compensation, and ratified HTL International, LLC as the independent auditor. KALA BIO operates in the biotechnology sector, focusing on drug discovery and development.
